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To find novel predictors of treatment response to disease-modifying antirheumatic drugs
(DMARDs), we studied activation of STAT (signal transducers and activators of transcrip-
tion) 6 and 1 in circulating leukocytes of patients with rheumatoid arthritis (RA).
Methods
19 patients with untreated recent-onset RA, 16 patients with chronic RA irresponsive to syn-
thetic DMARDs and 37 healthy volunteers provided blood samples for whole blood flow
cytometric determination of intracellular STAT6 and STAT1 phosphorylation, expressed as
relative fluorescence units, in response to IL-4 and IFN-γ, respectively. Phosphorylation
was restudied and treatment response (according to European League Against Rheuma-
tism) determined after 1-year treatment with synthetic DMARDs in recent-onset RA and with
biological DMARD in synthetic DMARD-irresponsive RA. Estimation-based exact logistic
regression was used to investigate relation of baseline variables to treatment response.
95% confidence intervals of means were estimated by bias-corrected bootstrapping and the
significance between baseline and follow-up values was calculated by permutation test.
Results
At baseline, levels of phosphorylated STAT6 (pSTAT6) induced by IL-4 in monocytes were
higher in those who achieved good treatment response to synthetic DMARDs than in those
who did not among patients with untreated RA (OR 2.74, 95% CI 1.05 to 9.47), and IFN-γ -stim-
ulated lymphocyte pSTAT1 levels were higher in those who achieved good treatment response
to a biological drug than in those who did not among patients with chronic RA (OR 3.91, 95%
CI 1.12 to 20.68). During follow-up, in recent-onset RA patients with good treatment response
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to synthetic DMARDS, the lymphocyte pSTAT6 levels decreased (p = 0.011), and, conse-
quently, the ratio of pSTAT1/pSTAT6 in lymphocytes increased (p = 0.042).
Conclusion
Cytokine-stimulated STAT6 and STAT1 phosphorylation in circulating leukocytes was asso-
ciated with treatment response to DMARDs in this pilot study. The result, if confirmed in
larger studies, may aid in developing personalized medicine in RA.
Introduction
Rheumatoid arthritis (RA) is a disease of autoimmune origin characterized by synovitis,
autoantibody production, cartilage and bone destruction, and systemic inflammation. RA is
predisposed by both genetic and environmental triggers, and complex adaptive and innate
immune mechanisms contribute to the disease course. [1] The treatment of patients with
newly diagnosed RA is usually started with traditional disease-modifying antirheumatic drugs
(DMARDs), and intensified, if necessary, by biological drugs, most commonly inhibitors of
the proinflammatory cytokines such as tumor necrosis factor (TNF) [2].
In order to maintain RA patients’ work capacity optimally, remission should be achieved
rapidly [3,4]. However, at present there are virtually no reliable biomarkers to predict treat-
ment response to the chosen treatment in RA. Several studies have been performed to examine
the usefulness of clinical and laboratory variables, autoantibodies, cytokines and genetic fac-
tors as predictors of treatment response to methotrexate and other types of DMARDs as well
as to anti-TNF agents and other biological drugs [5,6]. The most studied treatment response
marker candidates may be plasma levels of inflammatory cytokines and other soluble media-
tors. However, the results concerning the treatment response marker ability of these candi-
dates can be contradicting [5,7], or they may not provide additional predictive value to the
levels of inflammatory activity markers that are already in clinical use (primarily C-reactive
protein and erythrocyte sedimentation rate) [8–10]. Among demographics and clinical data,
the treatment strategy seems to be the strongest predictor [11]. Rheumatoid factor and antici-
trullinated protein antibodies may be used in clinical practice, as their presence has been
reported to associate with good treatment response to biologicals [12–14], but not uniformly,
either [15,16].
Immune cell profiling is a novel approach to find predictive markers in RA, including stud-
ies on cell surface marker determination [17–19], while studies on potential markers belonging
to intracellular signaling in immune cells are rare so far. Such markers could be, for example,
STAT (signal transduction and activator of transcription) family members, which are involved
in leukocyte signaling in response to various cytokines and growth factors, become activated
mainly by phosphorylation, and play important roles in immune responses [20]. STAT1 and
STAT6, for example, are tempting targets for marker research on RA for several reasons. First,
their expression is upregulated in synovial lymphocytes, macrophages and fibroblasts in
inflammatory arthritis and diminishes along with successful response to DMARDs [21–23].
However, these STATs have quite divergent effects. STAT1 elicits the Th1 type of immune
responses, interacts with Th17 type response development, activates inflammation, but also
exerts homeostatic functions and attenuates tissue destruction [24]. STAT6 promotes expres-
sion of several Th2-specific transcription factors and subsequent production of Th2 cytokines,
humoral immunity and regulatory T cell response [25,26]. Thus, the roles of STAT1 and
STAT6 in the continuum of the inflammatory process in the joints apparently differ from each
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other, and remain unresolved yet. Second, despite the obvious importance of STAT1 and
STAT6 on the immune response, their activation in circulating immune cells is not known,
especially in relation to each other. Third, while the effects of both the principal STAT1-acti-
vating cytokine IFN-γ and STAT6-activating IL-4 seem either advantageous or disadvanta-
geous depending on the phase of the arthritic disease or the animal model used [24,27,28],
activation of STAT1 and STAT6 in response to these cytokines with respect to the RA progres-
sion and treatment response remain largely unknown.
To the present study we recruited patients with recent-onset RA who had not started
DMARD therapy, another group of patients with chronic DMARD-irresponsive RA who
started biological therapy, and a reference group of healthy subjects, and determined STAT1
and STAT6 phosphorylation in circulating leukocyte subsets in response to cytokine stimula-
tion (IFN-γ and IL-4, respectively) using whole blood flow cytometry. The patients were exam-
ined at baseline and after one year of treatment and the data were analyzed in relation to the
activity and outcome of RA. To our knowledge, this is the first study to explore intracellular
signaling of both STAT1 and STAT6 pathways in circulating leukocyte subtypes with regard to
treatment response in RA.
Materials and Methods
Subjects
The study comprised two patient groups and a healthy reference group. Nineteen patients who
had been newly diagnosed with RA and not received DMARDs or oral corticosteroids prior to
blood sampling were the recent-onset RA group. Sixteen patients with persisting disease activ-
ity despite treatment with several synthetic DMARDs were the chronic RA group. Their blood
samples were obtained before initiating biological DMARD therapy. The patients were
recruited at the Division of Rheumatology, Helsinki University Central Hospital, from July
2010 to March 2012. An additional group consisting of 37 healthy subjects was recruited
among laboratory and hospital personnel who did not have autoimmune diseases or immuno-
suppressive medication. Their samples were used as references to ensure the comparability of
the activation results during the time span of the study.
All patients fulfilled the ACR/EULAR 2010 classification criteria for RA [29]. The study
protocol was approved by the Ethical Review Board of the Joint Authority for the Hospital Dis-
trict of Helsinki and Uusimaa. An informed written consent was obtained from each subject.
Clinical evaluation
A comprehensive clinical and laboratory evaluation was undertaken at entry concomitant to
blood sampling, and after follow-up time (median 10 months, range 5 to 24 months) to assess
outcome. 66/68 joints were evaluated for swelling and pain, patient’s global assessment of dis-
ease activity was recorded on a 100 mm visual analogue scale, and laboratory measurements
including erythrocyte sedimentation rate (ESR) and plasma C-reactive protein (CRP) level
were logged. Disease activity score using 28 joints with ESR (DAS28) was calculated [30].
Blood samples and leukocyte stimulation
A 4-ml blood sample was taken, at baseline and at follow-up, by venipuncture from the antecu-
bital vein into a Falcon polypropylene tube (Becton Dickinson, Lincoln Park, NJ) supple-
mented with 400 μl of pyrogen-free acid citrate dextrose solution A (ACD-A, Baxter Health
Care Ltd, Norfolk, UK). Aliquoting and stimulations were performed within 3 hours of blood
sampling.
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100-μl aliquots of blood were put into polystyrene tubes (BD) and stimulated either with
human recombinant IL-4 (R&D Systems, Minneapolis, MN) at final concentration of 10 ng/
ml for 10 min or with hrIFN-γ (R&D Systems) at final concentration of 100 ng/ml for 5 min at
+37˚C, or incubated without cytokine stimulation at +37˚C. After aliquoting, the tubes were
also supplemented with the monocyte surface marker antibody anti-CD14-FITC (mouse anti-
human IgG2b, κ, clone MφP9) (5 μl) (Becton Dickinson Biosciences, San Jose, CA).
Whole blood flow cytometric protocol
Blood samples were prepared using a protocol and reagents by Becton Dickinson [31]. Opti-
mal amounts of the antibodies and their compatibility with the permeabilization procedure, as
well as the cytokine stimulation conditions described above, were chosen based on preliminary
experiments. Unstimulated samples were used as controls because they provide the best means
to distinguish positive from negative events [32,33].
Following the initial incubations, leukocytes were fixed and erythrocytes lysed by adding
1X Lyse/Fix Buffer. After pelleting, leukocytes were washed with Stain Buffer and permeabi-
lized by Perm Buffer III at -20˚C for 30 min. Cells were pelleted and washed with Stain Buffer,
after which the tubes were supplemented with the T cell marker antibody anti-CD3-PerCP
(mouse anti-human IgG1, κ, clone SK7) (9 μl), and the IL-4 -stimulated tube and its unstimu-
lated control tube with anti-STAT6 (pTyr641) -Alexa Fluor 647 antibody (mouse anti-human
IgG2a, clone 18/P-Stat6) (5 μl), and the IFN-γ -stimulated tube and its unstimulated control
tube with anti-STAT1 (pTyr701) -Alexa Fluor 647 antibody (mouse anti-human IgG2a, clone
4a) (5 μl), in 100 μl of Stain Buffer. Following incubation at room temperature protected from
light for 20 min, cells were washed in Stain Buffer and resuspended in 300 μl of Stain Buffer.
The samples were kept on ice for a maximum of 4 hours until flow cytometric acquisition.
Flow cytometric data were acquired on FACSCantoII flow cytometer and analyzed with
FACSDiva software (BD), as described previously [34]. Monocytes were identified by their
CD14-positivity and light scattering characteristics (Fig 1A and 1B). Lymphocytes were identified
by their light scattering characteristics (Fig 1C). pSTAT1 and pSTAT6 fluorescence intensity his-
tograms were created for both stimulated and unstimulated lymphocytes and monocytes (for
examples, see Fig 1D–1G). The intensities were expressed as relative fluorescence units (RFU).
Statistical analysis
The data are presented as means with standard deviations (SD), medians with interquartile
range (IQR), or counts with percentages. Correlations were estimated by Spearman’s correla-
tion coefficient method. Estimation-based exact logistic regression was used to investigate rela-
tion of baseline variables to treatment response. In all analyses, patients with good EULAR
response were categorized as good responders and patients with moderate or no response as
non-responders. The 95% confidence intervals (CI) of means were estimated by bias-corrected
bootstrapping (5000 replications) and the significance of difference between baseline and fol-
low-up values was calculated by permutation test for paired replicates. Stata 13.1 (StataCorp
LP, College Station, TX, USA) statistical package was used for the analyses.
Results
Subjects and treatment
A total of 19 patients had recent-onset RA with a median duration of symptoms of 12 months
(interquartile range 4 to 24 months) and had not previously received any synthetic DMARDs
or oral glucocorticoids (Table 1). Another 16 patients had chronic RA with median disease
STAT6 and STAT1 in Rheumatoid Arthritis
PLOS ONE | DOI:10.1371/journal.pone.0167975 December 12, 2016 4 / 15
STAT6 and STAT1 in Rheumatoid Arthritis
PLOS ONE | DOI:10.1371/journal.pone.0167975 December 12, 2016 5 / 15
duration of 12.5 years (interquartile range 7 to 15.5 years) and were included in the study prior
to initiating their first biological DMARD (Table 1).
After blood sampling, 18 patients with recent-onset RA started DMARD therapy according
to the national guidelines [35] and EULAR recommendations [2]: 8 patients (42%) methotrex-
ate (MTX)-based combination, 3 patients (16%) other combination, 5 patients (26%) MTX
monotherapy, and 2 patients (11%) other monotherapy. In addition, 6 patients (32%) started a
course of low-dose ( 10 mg/day) oral prednison. During follow-up the drug treatment was
modified, targeting to remission, in line with the national and EULAR recommendations
Fig 1. Flow cytometry gating strategy. A) Gate P3 was set to comprise all events with high CD14-FITC-
fluorescence. B) Among events in P3, monocytes were included in gate P4 based on light scattering
characteristics (FSC and SSC). C) Gate P1 was set to comprise lymphocytes based on light scattering
characteristics, and for analysis all events in P1 but not in P4 were considered lymphocytes. Gate P2 was set
to comprise neutrophils. pSTAT6-Alexa Fluor 647 and pSTAT1-Alexa Fluor 647 fluorescence intensity
histograms were created for lymphocytes and monocytes in respective tubes. Representative histograms are
shown for comparatively high (D) and low (E) monocyte pSTAT6 activation, and comparatively high (F) and
low (G) lymphocyte pSTAT1 activation. Gate P5 (D, E) or P7 (F, G) is set to comprise 2–4% of events in the
unstimulated sample and copied to the corresponding stimulated sample, i.e. the unstimulated samples serve
as controls for the stimulated samples.
doi:10.1371/journal.pone.0167975.g001
Table 1. Characteristics of the subjects at baseline.
Variables Recent-onset RA (N = 19) Chronic RA (N = 16) Healthy subjects (N = 37)
Demographics
Women, n (%) 16 (84) 13 (81) 24 (65%)
Age (years), mean (SD) 46 (15) 48 (14) 37 (15)
Rheumatoid factor positive, n (%) 15 (79) 13 (81)
ACPA positive, n (%) 14 (74) 12 (80)
Measures of disease activity, mean (SD)
DAS28 3.79 (1.55) 4.79 (1.32)
Erythrocyte sedimentation rate (mm/h) 24 (23) 24 (15)
Plasma C-reactive protein (mg/l) 18 (26) 11 (9)
Number of swollen joints (0–66) 7 (5) 11 (7)
Number of tender joints (0–68) 7 (5) 12 (9)
Patient’s global assessment (VAS 0–100 mm) 45 (24) 51 (23)
pSTAT6, RFU, mean (SD)
IL-4 –stimulated monocytes 1240 (339) 1094 (287) 1054 (266)
Unstimulated monocytes 247 (31) 235 (65) 233 (38)
IL-4 –stimulated lymphocytes 382 (108) 348 (103) 312 (70)
Unstimulated lymphocytes 95 (12) 92 (17) 89 (14)
pSTAT1, RFU, mean (SD)
IFN-γ –stimulated monocytes 1967 (661) 1616 (537) 2087 (869)
Unstimulated monocytes 284 (39) 293 (48) 271 (33)
IFN-γ –stimulated lymphocytes 146 (20) 141 (24) 138 (21)
Unstimulated lymphocytes 109 (13) 199 (27) 100 (16)
pSTAT1/pSTAT6 ratio, mean (SD)
Monocytes 1.63 (0.50) 1.55 (0.56) 2.02 (0.74)
Lymphocytes 0.41 (0.11) 0.43 (0.12) 0.45 (0.09)
Abbreviations: RA, rheumatoid arthritis; ACPA, anti-citrullinated protein antibody; SD, standard deviation; DAS28, disease activity score in 28 joints; VAS,
visual analogue scale; pSTAT, phosphorylated signal transducer and activator of transcription; RFU, relative fluorescence units.
doi:10.1371/journal.pone.0167975.t001
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[35,2]. At follow-up, 1 patient had stopped DMARD treatment and 3 patients had stopped oral
prednison. The EULAR treatment response was good in 11 patients (58%), moderate in 2
patients (11%), and 6 patients (32%) did not respond.
In the chronic RA group, 14 patients started an anti-TNF drug (5 golimumab, 4 etanercept,
3 adalimumab, and 2 certolizumab), 1 patient started tocilizumab, and 1 patient rituximab. In
addition to biologicals, 6 patients (38%) used a MTX-based DMARD combination, 4 patients
(25%) other DMARD combination, 2 patients (13%) MTX monotherapy, and 2 patients (13%)
other DMARD monotherapy. In addition, 9 patients (56%) used low-dose ( 10 mg/day) oral
prednison. During follow-up one patient stopped rituximab treatment and 3 patients were
switched to another TNF blocker. The EULAR treatment response was good in 10 patients
(63%), moderate in 3 patients (19%), and 3 patients (19%) did not respond.
At baseline, pSTAT6 and pSTAT1 levels and the pSTAT1/pSTAT6 ratio did not correlate
with age, erythrocyte sedimentation rate, or CRP (Table 2).
pSTAT6 predicts treatment response to DMARDs in recent-onset RA
and decreases during successful treatment
Among patients with recent-onset RA, baseline STAT6 phosphorylation (pSTAT6) levels upon
IL-4 stimulation in monocytes were higher in those who achieved good response to DMARDs
than in those who did not (Table 3). IFN-γ -stimulated pSTAT1 levels and the ratio of IFN-γ-
stimulated pSTAT1 to IL-4 -stimulated pSTAT6 of these patients at baseline were not associated
with response to DMARDs (Table 3). Also, pSTAT6 and pSTAT1 levels and the pSTAT1/
pSTAT6 ratio did not correlate with disease activity determined by DAS28 (data not shown).
During follow-up, pSTAT6 levels fell significantly among good responders in monocytes
and lymphocytes (Fig 2A and 2D), while there were no significant changes in pSTAT1 levels
(Fig 2B and 2E). This led to an increase in the pSTAT1/pSTAT6 ratios (Fig 2C and 2F), which
was significant in good responders’ lymphocytes (Fig 2F).
pSTAT1 predicts treatment response to biological drugs in chronic RA
Among patients with chronic RA, baseline pSTAT1 levels upon IFN-γ stimulation in lympho-
cytes were higher in those who achieved good response to biological drug in than in those who
did not (Table 3). IL-4 -stimulated pSTAT6 levels and the ratio of IFN-γ-stimulated pSTAT1
Table 2. Correlation of signaling results with age and inflammatory markers at baseline in all
patients.
Age, years ESR, mm/h CRP, mg/l
Baseline r (95% CI) r (95% CI) r (95% CI)
Monocyte
pSTAT6, RFU 0.14 (-0.21 to 0.45) 0.03 (-0.30 to 0.36) 0.11 (-0.23 to 0.43)
pSTAT1, RFU -0.20 (-0.50 to 0.14) 0.08 (-0.26 to 0.40) 0.28 (-0.06 to 0.56)
pSTAT1/pSTAT6 ratio -0.32 (-0.59 to 0.01) -0.01 (-0.34 to 0.33) 0.18 (-0.16 to 0.49)
Lymphocyte
pSTAT6, RFU 0.20 (-0.14 to 0.50) 0.12 (-0.22 to 0.44) 0.17 (-0.17 to 0.48)
pSTAT1, RFU -0.06 (-0.38 to 0.28) 0.26 (-0.08 to 0.55) 0.26 (-0.08 to 0.54)
pSTAT1/pSTAT6 ratio -0.25 (-0.54 to 0.10) 0.02 (-0.31 to 0.36) 0.01 (-0.32 to 0.34)
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; r, Spearman correlation coefficient; CI,
confidence interval; pSTAT, phosphorylated signal transducer and activator of transcription, RFU, relative
fluorescence units.
doi:10.1371/journal.pone.0167975.t002
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to IL-4 -stimulated pSTAT6 of these patients at baseline were not associated with response to
biological treatment (Table 3). pSTAT6 and pSTAT1 levels and the pSTAT1/pSTAT6 ratio did
not correlate with disease activity determined by DAS28 (data not shown).
During follow-up, pSTAT6 levels fell significantly in monocytes and lymphocytes (Fig 3A
and 3D), while there were no significant changes in pSTAT1 levels (Fig 3B and 3E). This led to
a non-significant but clear increase in the pSTAT1/pSTAT6 ratios in good responders’ mono-
cytes and lymphocytes (Fig 3C and 3F).
Discussion
Our results reveal that baseline STAT6 phosphorylation level, as determined by whole blood
phospho-specific flow cytometry, in monocytes upon IL-4 stimulation is positively correlated
with good treatment response to synthetic DMARDs in patients with recent-onset untreated
RA, and, that baseline STAT1 phosphorylation level in lymphocytes upon IFN-γ stimulation is
positively correlated with good treatment response to biological drugs in patients with chronic
RA. The findings are novel and suggest that activation capability of STAT6 and STAT1 signal-
ing pathways of circulating leukocytes may aid to predict treatment response in RA patients.
We also found recently that baseline STAT3 phosphorylation in peripheral blood CD4+ T cells
is associated with good treatment response to synthetic DMARDs in recent-onset RA [36].
Immune cell profiling strategies other than above have also been applied to find predictive
markers in RA [37]. These include determination of the expression of chemokine receptors on
T cells and monocytes for predicting response to infliximab [17], CD28 on T cells for predict-
ing response to abatacept [18], CD16 on monocytes for predicting response to methotrexate
[19], and ZAP-70 in B cells for predicting response to rituximab [38]. Taken together, immune
cell profiling is a promising approach to be used in guiding personalized treatment decisions
and improving outcomes of patients with RA.
The mechanisms underlying the positive correlation between STAT6 phosphorylation level
and response to DMARDs are not known but may involve priming of circulating cells. Indeed,
inflammatory stimuli like autoantibodies and Toll-like receptor ligands may up-regulate IL-4
receptor expression to cause priming for STAT6 signaling in myeloid cells. This, in turn, can
limit excessive inflammation and tissue damage. [39] Also, high percentage of IL-4 positive
CD4+ T cells at onset of RA has been reported to predict remission with methotrexate treat-
ment [40]. Furthermore, it has been shown in mouse models that deficiency of IL-4 and
Table 3. Univariate odds ratios of good EULAR response calculated by estimation-based exact logistic regression.
Recent-onset RA Chronic RA
Baseline OR* (95% CI) p value OR* (95% CI) p value
Monocyte
pSTAT6, RFU 2.74 (1.05 to 9.47) 0.037 1.91 (0.64 to 6.72) 0.27
pSTAT1, RFU 2.45 (0.76 to 9.66) 0.14 1.68 (0.48 to 6.72) 0.44
pSTAT1/pSTAT6 ratio 0.86 (0.25 to 2.85) 0.81 1.08 (0.36 to 3.35) 0.89
Lymphocyte
pSTAT6, RFU 2.25 (0.91 to 7.40) 0.084 2.37 (0.81 to 11.25) 0.13
pSTAT1, RFU 1.76 (0.63 to 5.58) 0.30 3.91 (1.12 to 20.68) 0.029
pSTAT1/pSTAT6 ratio 0.59 (0.22 to 1.41) 0.25 0.85 (0.33 to 2.09) 0.74
* per 1 standard deviation.
Abbreviations: EULAR, European League Against Rheumatism; RA, rheumatoid arthritis; OR, odds ratio; CI, confidence interval; pSTAT, phosphorylated
signal transducer and activator of transcription, RFU, relative fluorescence units.
doi:10.1371/journal.pone.0167975.t003
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Fig 2. pSTAT6 and pSTAT1 in patients with recent-onset rheumatoid arthritis (n = 19). IL-4-induced pSTAT6
(A, D) and IFN-γ-induced pSTAT1 (B, E) fluorescence intensities and their ratios (C, F) in peripheral blood
monocytes (A-C) and lymphocytes (D-F). Measurements were made before treatment (“Baseline”) and after 1-year
treatment with disease-modifying antirheumatic drugs (“Follow-up”). Results are shown separately for patients with
no or moderate treatment response (“No”, n = 7) or good response (“Good”, n = 12), as defined by EULAR criteria.
The fluorescence intensities are given in relative fluorescence units (RFU), with squares denoting group means and
whiskers denoting 95% confidence intervals. The horizontal dashed lines show the corresponding mean values in
healthy controls (n = 37). The p values denote significance of difference between baseline and follow-up values
(permutation test). Predictive value of baseline levels for treatment response are shown in Table 2. Abbreviations:
STAT6 and STAT1 in Rheumatoid Arthritis
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STAT6 can result in significant increase in arthritis severity [28], and that overexpression of
IL-4 may protect from cartilage erosions [41]. Hence, good response to DMARDs in recent-
onset RA may be associated with monocytes’ good capability for IL-4 -mediated responses that
protect from progression of tissue destruction associated with RA.
Our observation that there is a positive correlation between IFN-γ -stimulated STAT1 phos-
phorylation level in circulating lymphocytes and treatment response to biological drugs in
patients with chronic RA may reflect an overall immunological state that is facilitated by good
STAT1 activation capability. Supporting this concept, it has been reported recently that IFN-γ
inhibits IL-17 production in a STAT1-dependent manner, thus representing one mechanism
favoring the development of Th1 cells and silencing the Th17 program [42]. Furthermore,
Ortiz et al. showed that levels of IFN-γ -induced pSTAT1 positive cells in peripheral blood of
RA patients correlate inversely with the number of memory T cells, and, close to our finding,
that baseline levels of the IFN-γ -induced pSTAT1+ cells are higher in those RA patients who
obtain good response to the IL-6 blocker tocilizumab [43]. Altogether, it is possible that higher
capacity to phosphorylate STAT1 in response to IFN-γ can be a marker able to distinguish the
RA patients who are amenable to treatment with TNF or IL-6 blockers. This needs to be veri-
fied in larger studies, as well as the possibility that the same applies to additional biologicals.
In the present study we also found that STAT6 phosphorylation decreases during treat-
ment, which agrees with the finding that STAT6 expression decreases in response to successful
DMARD treatment in the RA synovium [21]. The mechanisms that are able to attenuate
STAT6 phosphorylation include negative feedback provided by members of the suppressors of
cytokine signaling family, which may regulate IL-4-dependent STAT6 activation [44] and are
elevated in RA patients’ peripheral blood mononuclear cells [45]. As to lymphocyte STAT1
phosphorylation in chronic RA patients not responding to multiple synthetic DMARDs, high
baseline levels predicted good response to biologicals and did not decrease during the therapy.
If confirmed in larger studies, STAT1 phosphorylation could serve as a predictive surrogate
marker identifying a subgroup of patients with chronic RA who will have good treatment
response to biologicals.
In order to evaluate the relationship of combined markers with the treatment response, we
calculated the ratio of IFN-γ -stimulated STAT1 phosphorylation to IL-4 -stimulated STAT6
phosphorylation in leukocytes. The ratio may indicate how the immune response types are ori-
entated, especially as IFN-γ has been shown sufficient for Th1 differentiation, whereas IL-4 is
critical for Th2 differentiation [46]. We found no association between the pSTAT1/pSTAT6
ratio at baseline and treatment response, but, however, the ratio increased during treatment
with synthetic or biological DMARDs, and the increase was significant in lymphocytes during
successful DMARD treatment in recent-onset RA. Our findings are consistent with results
showing that a shift to the Th1 direction occurred in the Th1/Th2 cell ratio in patients with
RA during either TNF blocker or glucocorticoid treatment [47], and that the expression of
IFN-γ compared to that of IL-4 in peripheral blood mononuclear culture increased under
treatment with the TNF antibody infliximab [48]. IFN-γ can suppress IL-4 -induced STAT6
activation, as observed in monocytes and Th1 cells [49,50]. Altogether, the increased pSTAT1/
pSTAT6 ratio after follow-up observed in our study seems to be more due to a decrease in
STAT6 phosphorylation capability than an increase in STAT1 phosphorylation capability.
Although pSTAT1 and pSTAT6 predicted treatment response, of interest, they did not cor-
relate with DAS28, suggesting that the two markers are distinct from disease activity markers.
pSTAT, phosphorylated signal transducer and activator of transcription, EULAR, European League Against
Rheumatism.
doi:10.1371/journal.pone.0167975.g002
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Fig 3. pSTAT6 and pSTAT1 in patients with chronic rheumatoid arthritis (n = 16). IL-4 -induced pSTAT6 (A, D)
and IFN-γ -induced pSTAT1 (B, E) fluorescence intensities and their ratios (C, F) in peripheral blood monocytes
(A-C) and lymphocytes (D-F). Measurements were made before treatment (“Baseline”) and after 1-year treatment
with biological drugs (“Follow-up”). Results are shown separately for patients with no or moderate treatment
response (“No”, n = 6) or good response (“Good”, n = 10), as defined by EULAR criteria. The fluorescence intensities
are given in relative fluorescence units (RFU), with squares denoting group means and whiskers denoting 95%
confidence intervals. The horizontal dashed lines show the corresponding mean values in healthy controls (n = 37).
The p-values denote significance of difference between baseline and follow-up values (permutation test). Predictive
STAT6 and STAT1 in Rheumatoid Arthritis
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The only correlation observed between disease activity measures and pSTAT6 and pSTAT1
phosphorylation was a positive correlation between the pSTAT1/pSTAT6 ratio at study entry
and swollen joint count. This feature may reflect the potent effects of the IFN-γ/STAT1 path-
way within joints, including priming of monocytes and macrophages and induction of inflam-
matory mediator production [51]. This is likely to represent the complexity of the cellular and
molecular interactions involving IFN-γ/STAT1 and IL-4/STAT6 pathways during different
phases of RA, which is also evident in the opposing results obtained from other studies. There
are studies showing that in human peripheral blood leukocytes, the IFN-γ/STAT1 pathway is
able to limit cellular infiltration and potential tissue damage at inflammatory sites [52,53].
Also, in certain mouse models, the IFN-γ/STAT1 pathway mediates protective effects in auto-
immune disease and arthritis [24], and lack of IL-4 and STAT6 suppresses arthritis [27]. How-
ever, in other mouse models, the IFN-γ/STAT1 pathway has increased and the IL-4/STAT6
pathway decreased the severity of arthritis [28]. Clearly, further studies are required to reveal
the mechanisms explaining our results on the associations of IL-4/STAT6 and IFN-γ/STAT1
signaling in immune cells and the course of RA.
A lthough there was significant association between STAT6 and STAT1 phosphorylation
levels and treatment response in RA, the levels overlapped with those of healthy reference sub-
jects. However, among the numerous inflammatory pathways operating in RA, it is important
to find the specific molecular markers that are able to distinguish the patients who will respond
to a given treatment from those who will not, even if the markers serve as surrogate markers.
As the method used in the present study allows determining phosphorylation and/or expres-
sion of several targets simultaneously, it is applicable for combining or correlating STAT1 and
STAT6 phosphorylation with other markers, thereby possibly creating markers that can be uti-
lized in tailoring personalized treatment for patients with RA in the future. The patients stud-
ied were well characterized with rigorous inclusion criteria, although the number of patients
brands this a pilot study.
Conclusion
Our current results show that baseline STAT6 and STAT1 phosphorylation levels in circulat-
ing leukocytes are associated with treatment response to synthetic DMARDs and biologicals in
RA, and that their ratio is influenced by the treatments. If confirmed in larger studies, the
results may be utilized in developing personalized medicine for patients with RA.
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